Financiado en parte por Natural Remedies Pvt. Ltd.
Efficacy and Safety of Low-Dose Ashwagandha Supplementation on Exercise Endurance: A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial
Prajapati H, Satia M, Shah D, Basera I, Shah T
Phytotherapy research : PTR · 1 cita
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Natural Remedies Pvt. Ltd.
Según 1 financiador declarado.
Publicación
- Publicado
- 2026-03-17 · Phytother Res · vol. 40 · número 8 · págs. 4978–4987
- Editorial
- Wiley
- Citado
- 1 cita · más que el 95% de estudios similares · 9.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 21 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Medicinal Plants and Bioactive Compounds · Exercise and Physiological Responses
- Palabras clave
- Withania somnifera, low-dose supplementation, withanolides, exercise endurance, cardiorespiratory fitness, VO2max, exercise fatigue, lactic acid, creatine kinase, rating of perceived exertion, adaptogens, exercise performance
- MeSH
- humans, withania, fatigue, lactic acid, creatine kinase, plant extracts, exercise test, exercise, double-blind method, oxygen consumption, heart rate, physical endurance, dietary supplements, adult, female, male, young adult, cardiorespiratory fitness
5 autores
- Himanshu Prajapati
- Milan Satia
- Dhara Shah · autor de correspondencia
- Ishita Basera
- Tanvi Shah
Resumen
El texto original del estudio, en el idioma en que se publicó.
Ashwagandha ( Withania somnifera ) is a well-known adaptogen with established roles in stress modulation and physical performance enhancement traditionally. Low dose Ashwagandha (LDA/Ashwa.30) is a bioactive-optimized root-only extract standardized to withanolides (> 15% w/w) and an ATP-active fraction (> 15% w/w). This study investigated the efficacy and safety of LDA supplementation on cardiorespiratory fitness and exercise-induced fatigue in healthy individuals. In this eight-week, randomized, double-blind, placebo-controlled study, healthy adults received either LDA (30 mg/day) or placebo. VO2max was assessed as primary endpoint using an indirect method via the Modified Bruce Protocol Treadmill Test (MBPTT). Secondary endpoints included lactic acid, creatine phosphokinase (CPK), Rating of Perceived Exertion (RPE), fatigue scores (VAS), and safety biomarkers. LDA significantly improved VO2max and maximal heart rate compared to the placebo. Participants in the treatment group showed lower lactic acid levels at exercise, indicating prolonged aerobic metabolism. CPK levels were significantly reduced, suggesting mitigation of muscle energy stress. Borg RPE and fatigue scores improved in the LDA group. LDA was well tolerated, with no treatment-related adverse events. Hematological, hepatic, renal, metabolic, and vital sign parameters remained within normal clinical ranges following intake of LDA. LDA supplementation for 8 weeks significantly enhanced cardiorespiratory fitness, delayed fatigue onset, and was safe for use in healthy adults. These findings support its potential as a safe and effective low-dose aid for endurance enhancement and overall exercise performance.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.